Puma Biotechnology, Inc. (PBYI)
10.30
0.00 (0.00%)
USD |
NASDAQ |
Oct 12, 16:00
10.30
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Free Cash Flow (Quarterly) : 1.624M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.624M |
| March 31, 2026 | 15.42M |
| December 31, 2025 | 14.46M |
| September 30, 2025 | 9.663M |
| June 30, 2025 | 14.06M |
| March 31, 2025 | 3.551M |
| December 31, 2024 | 15.59M |
| September 30, 2024 | 11.02M |
| June 30, 2024 | 1.007M |
| March 31, 2024 | 11.25M |
| December 31, 2023 | 10.41M |
| September 30, 2023 | 10.59M |
| June 30, 2023 | 3.228M |
| March 31, 2023 | -9.857M |
| December 31, 2022 | 7.683M |
| September 30, 2022 | 17.26M |
| June 30, 2022 | -13.87M |
| March 31, 2022 | -26.90M |
| December 31, 2021 | -5.435M |
| September 30, 2021 | 10.50M |
| June 30, 2021 | -0.074M |
| March 31, 2021 | 15.66M |
| December 31, 2020 | -15.66M |
| September 30, 2020 | 1.709M |
| June 30, 2020 | 6.216M |
| Date | Value |
|---|---|
| March 31, 2020 | -11.54M |
| December 31, 2019 | 1.26M |
| September 30, 2019 | -7.307M |
| June 30, 2019 | 44.25M |
| March 31, 2019 | -16.13M |
| December 31, 2018 | 6.988M |
| September 30, 2018 | -7.567M |
| June 30, 2018 | -17.84M |
| March 31, 2018 | -6.293M |
| December 31, 2017 | -85.75M |
| September 30, 2017 | -55.06M |
| June 30, 2017 | -45.92M |
| March 31, 2017 | -36.17M |
| December 31, 2016 | -41.52M |
| September 30, 2016 | -34.96M |
| June 30, 2016 | -37.43M |
| March 31, 2016 | -35.07M |
| December 31, 2015 | -33.09M |
| September 30, 2015 | -37.02M |
| June 30, 2015 | -34.90M |
| March 31, 2015 | -50.64M |
| December 31, 2014 | -19.09M |
| September 30, 2014 | -24.45M |
| June 30, 2014 | -17.70M |
| March 31, 2014 | -17.26M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | -2.133M |
| Arcutis Biotherapeutics, Inc. | 12.48M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Savara, Inc. | -29.97M |